Zuojinwan Combined With Chemotherapy and Cetuximab for Advanced Colorectal Cancer: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

适应症

试验速览

暂无简介。

•1. Patients who are diagnosed as colorectal cancer by pathology, cytology or imaging, and whose histological type is carcinoma, mucinous adenocarcinoma, signet ring cell carcinoma;
•2. Colorectal cancer patients with stage IV according to AJCC staging;
•3. RAS, BRAF wild-type, advanced unresectable colorectal cancer patients receiving chemotherapy combined with cetuximab;
•4. After PET-CT, CT, MRI, bone scan and other imaging examinations, there is at least one measurable lesion;
•5. TCM syndrome differentiation belongs to the syndrome of liver fire offending the stomach;
•6. 18 years old <= age <= 80 years old;
•7. KPS >= 60 points;
•8. Estimated survival time >= 3 months;
•9. Blood routine, liver function, kidney function, and heart function are generally normal, in line with chemotherapy indications;
•10. Have good compliance and sign informed consent to cooperate with this research.

•1. Combined with other primary tumors;
•2. Patients with severe cardiovascular and cerebrovascular diseases or severe mental illness;
•3. Those who have used chemotherapy or Chinese medicine for less than 2 cycles;
•4. Patients with active tuberculosis or infection;
•5. Those who are unable to take drugs orally;
•6. Those who have poor compliance and cannot complete the research;
•7. Those who have participated in other clinical trials in the past month.
•8. Women during pregnancy or breastfeeding.

发起方